Seffalair Spiromax Den europeiske union - norsk - EMA (European Medicines Agency)

seffalair spiromax

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - legemidler for obstruktive sykdommer i luftveiene, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Singulair 5 mg Norge - norsk - Statens legemiddelverk

singulair 5 mg

n.v. organon - kloosterstraat - montelukastnatrium - tyggetablett - 5 mg

Singulair 4 mg Norge - norsk - Statens legemiddelverk

singulair 4 mg

merck sharp & dohme b.v. - montelukastnatrium - granulat i dosepose - 4 mg

Singulair 10 mg Norge - norsk - Statens legemiddelverk

singulair 10 mg

n.v. organon - kloosterstraat - montelukastnatrium - tablett, filmdrasjert - 10 mg

Singulair 4 mg Norge - norsk - Statens legemiddelverk

singulair 4 mg

n.v. organon - kloosterstraat - montelukastnatrium - tyggetablett - 4 mg

Singulair 10 mg Norge - norsk - Statens legemiddelverk

singulair 10 mg

orifarm as - montelukastnatrium - tablett, filmdrasjert - 10 mg

Singulair 10 mg Norge - norsk - Statens legemiddelverk

singulair 10 mg

orifarm as - montelukastnatrium - tablett, filmdrasjert - 10 mg

Singulair 4 mg Norge - norsk - Statens legemiddelverk

singulair 4 mg

orifarm as - montelukastnatrium - tyggetablett - 4 mg

Singulair 5 mg Norge - norsk - Statens legemiddelverk

singulair 5 mg

orifarm as - montelukastnatrium - tyggetablett - 5 mg

Singulair 10 mg Norge - norsk - Statens legemiddelverk

singulair 10 mg

orifarm as - montelukastnatrium - tablett, filmdrasjert - 10 mg